Collaboration between pharmaceutical companies and patient advocates typically requires both parties to sign contracts covering various topics. These written agreements can often be too long and complex, and can be ambiguous in nature.
That’s why the multi-stakeholder project “Reasonable agreements between patient advocates and pharmaceutical companies” (an initiative led by WECAN with the collaboration of PFMD) aims to improve these legal agreements between both parties while providing adequate protection and rules for both sides.
You can check out here the principles developed by the group for reasonable legal agreements. The partnership is now working on developing contract templates for agreements on collaborations, advisory boards, speaking opportunities, and consultancy, with the first contract template for advisory board agreements currently being reviewed by partners. Watch this space for more updates.
